High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma

Journal of Clinical Oncology

Volumn 24, Issue 36, 2006, Pages 5630-5636

  Licitra, Lisa ^a   Perrone, Federica ^a   Bossi, Paolo ^a   Suardi, Simona ^a   Mariani, Luigi ^a   Artusi, Raffaella ^a   Oggionni, Maria ^a   Rossini, Chiara ^a   Cantù, Giulio ^a   Squadrelli, Massimo ^a   Quattrone, Pasquale ^a   Locati, Laura D ^a   Bergamini, Cristiana ^a   Olmi, Patrizia ^a   Pierotti, Marco A ^a   Pilotti, Silvana ^a  

^a FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; PROTEIN E7; PROTEIN P16INK4A; VIRUS DNA;

AMINO ACID SEQUENCE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA TUMOR VIRUS; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HIGH RISK BEHAVIOR; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; ONCOGENE; OROPHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; WART VIRUS; ADULT; AGED; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; OROPHARYNX TUMOR; PAPILLOMA VIRUS; RISK FACTOR; SECOND CANCER; SURVIVAL; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; VIROLOGY; VIRUS INFECTION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENES, P16; GENES, P53; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 34247331367     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.6136     Document Type: Article

References (53)

1. Li W, Thompson CH, O'Brien CJ, et al: Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 106:553-558, 2003
2. Mellin H, Dahlgren L, Munck-Wikland E, et al: Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 102:152-158, 2002
3. Lindel K, Beer KT, Laissue J, et al: Human papillomavirus positive squamous cell carcinoma of the oropharynx: A radiosensitive subgroup of head and neck carcinoma. Cancer 92:805-813, 2001
4. Schwartz SR, Yueh B, McDougall JK, et al: Human papillomavirus infection and survival in oral squamous cell cancer: A population-based study. Otolaryngol Head Neck Surg 125:1-9, 2001
5. Li W, Thompson CH, Cossart YE, et al: The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head Neck 26:1-9, 2004
6. Haraf DJ, Nodzenski E, Brachman D, et al: Human papilloma virus and p53 in head and neck cancer: Clinical correlates and survival. Clin Cancer Res 2:755-762, 1996
7. Ringstrom E, Peters E, Hasegawa M, et al: Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8:3187-3192, 2002
8. Paz IB, Cook N, Odom-Maryon T, et al: Human papillomavirus (HPV) in head and neck cancer: An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 79:595-604, 1997
9. Smith EM, Ritchie JM, Summersgill KF, et al: Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 108:766-772, 2004
10. Sisk EA, Bradford CR, Jacob A, et al: Human papillomavirus infection in "young" versus "old" patients with squamous cell carcinoma of the head and neck. Head Neck 22:649-657, 2000
11. Herrero R, Castellsague X, Pawlita M, et al: Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95:1772-1783, 2003
12. Sisk EA, Soltys SG, Zhu S, et al: Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 24:841-849, 2002
13. Hafkamp HC, Speel EJ, Haesevoets A, et al: A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 107:394-400, 2003
14. Ritchie JM, Smith EM, Summersgill KF, et al: Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 104:336-344, 2003
15. Clayman GL, Stewart MG, Weber RS, et al: Human papillomavirus in laryngeal and hypopharyngeal carcinomas: Relationship to survival. Arch Otolaryngol Head Neck Surg 120:743-748, 1994
16. Strome SE, Savva A, Brissett AE, et al: Squamous cell carcinoma of the tonsils: A molecular analysis of HPV associations. Clin Cancer Res 8:1093-1100, 2002
17. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720, 2000
18. Gallo O, Chiarelli I, Boddi V, et al: Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer 84:573-579, 1999
19. Braakhuis BJ, Snijders PJ, Keune WJ, et al: Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 96:998-1006, 2004
20. Butz K, Whitaker N, Denk C, et al: Induction of the p53-target gene GADD45 in HPV-positive cancer cells. Oncogene 18:2381-2386, 1999
21. Begum S, Gillison ML, Ansari-Lan MA, et al: Detection of human papillomavirus in cervical lymph nodes: A highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9:6469-6475, 2003
22. Braakhuis BJ, Tabor MP, Leemans CR, et al: Second primary tumors and field cancerization in oral and oropharyngeal cancer: Molecular techniques provide new insights and definitions. Head Neck 24:198-206, 2002
23. Birindelli S, Perrone F, Oggionni M, et al: Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 81:833-844, 2001
24. Josefsson AM, Magnusson PK, Ylitalo N, et al: Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study. Lancet 355: 2189-2193, 2000
25. Peitsaro P, Johansson B, Syrjanen S: Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40:886-891, 2002
26. Perrone F, Oggionni M, Birindelli S, et al: TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Int J Cancer 105:196-203, 2003
27. Pilotti S, D'Amato L, Della TG, et al: Papillomavirus, p53 alteration, and primary carcinoma of the vulva. Diagn Mol Pathol 4:239-248, 1995
28. Korn EL, Dorey FJ: Applications of crude incidence curves. Stat Med 11:813-829, 1992
29. Koch WM, Brennan JA, Zahurak M, et al: p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:1580-1586, 1996
30. Licitra L, Suardi S, Bossi P, et al: Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol 22: 4901-4906, 2004
31. Ahomadegbe JC, Barrois M, Fogel S, et al: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome: Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10:1217-1227, 1995
32. Alsner J, Sorensen SB, Overgaard J: TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol 59:179-185, 2001
33. Cabelguenne A, Blons H, de Waziers I, et al: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. J Clin Oncol 18: 1465-1473, 2000
34. Temam S, Flahault A, Perie S, et al: p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18:385-394, 2000
35. Yuen PW, Man M, Lam KY, et al: Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol 55:58-60, 2002
36. Weinberger PM, Yu Z, Haffty BG, et al: Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 10:5684-5691, 2004
37. DeWeese TL, Walsh JC, Dillehay LE, et al: Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. Int J Radiat Oncol Biol Phys 37:145-154, 1997
38. Mellin H, Friesland S, Lewensohn R, et al: Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival. Int J Cancer 89:300-304, 2000
39. Friesland S, Mellin H, Munck-Wikland E, et al: Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma: Relation to radiotherapy response and survival. Anticancer Res 21:529-534, 2001
40. Obata A, Eura M, Sasaki J, et al: Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer 89:187-193, 2000
41. Kessis TD, Slebos RJ, Nelson WG, et al: Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A 90:3988-3992, 1993
42. Wang Y, Okan I, Pokrovskaja K, et al: Abrogation of p53-induced G1 arrest by the HPV 16 E7 protein does not inhibit p53-induced apoptosis. Oncogene 12:2731-2735, 1996
43. Song S, Gulliver GA, Lambert PF: Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci U S A 95:2290-2295, 1998
44. Tindle RW, Frazer IH: Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr Top Microbiol Immunol 186:217-253, 1994
45. Bosch FX, Rohan T, Schneider A, et al: Papillomavirus research update: Highlights of the Barcelona HPV 2000 International Papillomavirus Conference. J Clin Pathol 54:163-175, 2001
46. Califano J, van der Riet P, Westra W, et al: Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56:2488-2492, 1996
47. Braakhuis BJ, Leemans CR, Brakenhoff RH: A genetic progression model of oral cancer: Current evidence and clinical implications. J Oral Pathol Med 33:317-322, 2004
48. Braakhuis BJ, Tabor MP, Kummer JA, et al: A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res 63:1727-1730, 2003
49. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, et al: Genetically altered fields as origin of locally recurrent head and neck cancer: A retrospective study. Clin Cancer Res 10:3607-3613, 2004
50. Jang SJ, Chiba I, Hirai A, et al: Multiple oral squamous epithelial lesions: Are they genetically related? Oncogene 20:2235-2242, 2001
51. Smith EM, Ritchie JM, Summersgill KF, et al: Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 96:449-455, 2004
52. Kresty LA, Mallery SR, Knobloch TJ, et al: Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res 62:5295-5300, 2002
53. Gillison ML: Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31:744-754, 2004